case_images: PMC11832547_01
case_images: Myeloid engraftment occurred on day 17 (A) and platelet engraftment occurred on day 43 (B) after the second transplantation.
case_images: fimmu-16-1495666-g001.jpg
case_images: PMC11832547_01_fimmu-16-1495666-g001.jpg
case_images: f1
case_images: Neutrophils were engrafted on day 17, and a platelet count of more than 20 x 109/L was achieved on day 43 ( Figure 1 ). T cell, B cell, and natural killer-cell development ( Figures 1 ,  2 ). There was no aGVHD, and the EBV PCR (polymerase chain reaction) results remained negative after day 14.
case_images: Patterns of CD3+, CD4+, CD8+, CD19+ and NK+ recovery post second transplant.
case_images: fimmu-16-1495666-g002.jpg
case_images: PMC11832547_01_fimmu-16-1495666-g002.jpg
case_images: f2
case_images: B lymphocyte (CD19+) counts were low or undetectable throughout the first 6 months posttransplant and increased steadily afterwards, reaching the normal range at 2 years ( Figure 2 ). T cell, B cell, and natural killer-cell development ( Figures 1 ,  2 ). There was no aGVHD, and the EBV PCR (polymerase chain reaction) results remained negative after day 14.
case_images: Variation in cytomegaloviral load with T-cell immune reconstitution after second transplant.
case_images: fimmu-16-1495666-g003.jpg
case_images: PMC11832547_01_fimmu-16-1495666-g003.jpg
case_images: f3
case_images: This strain was treated with therapeutic doses of foscarnet and became undetectable on day 75 posttransplant ( Figure 3 ).